Addex Therapeutics Ltd (SWX:ADXN)
0.0300
+0.0084 (38.89%)
Nov 12, 2026, 12:12 PM CET
Addex Therapeutics Employees
Addex Therapeutics had 3 employees as of December 31, 2025. The number of employees increased by 1 or 50.00% compared to the previous year. That makes Addex Therapeutics the 43,018th largest employer in the world and 193rd in Switzerland.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
27.69K CHF
Profits / Employee
-2.29M CHF
Market Cap
6.61M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3 | 1 | 50.00% |
| Dec 31, 2024 | 2 | -21 | -91.30% |
| Dec 31, 2023 | 23 | -1 | -4.17% |
| Dec 31, 2022 | 24 | -2 | -7.69% |
| Dec 31, 2021 | 26 | -1 | -3.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bachem Holding AG | 2,725 |
| Idorsia | 487 |
| Basilea Pharmaceutica AG | 200 |
| Molecular Partners AG | 134 |
| Santhera Pharmaceuticals Holding AG | 94 |
| BioVersys AG | 38 |
| Newron Pharmaceuticals | 27 |
| Xlife Sciences AG | 20 |
Addex Therapeutics News
- 3 hours ago - Addex Shares Surge As Neurosterix Closes $105M Financing To Advance Schizophrenia Program - Nasdaq
- 13 hours ago - Addex Spin-out Neurosterix Closes $105 Million Series B Financing - GlobeNewsWire
- 13 days ago - Addex Therapeutics Ltd Increases Issued Share Capital to Create Treasury Shares - Nasdaq
- 14 days ago - ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES - GlobeNewsWire
- 4 weeks ago - Addex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia Trial - Nasdaq
- 5 weeks ago - Addex Therapeutics spin-out company completes NTX-253 clinical studies - TheFly
- 5 weeks ago - Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia - GlobeNewsWire
- 5 weeks ago - Addex's Rocher Returns As Head Of Pharmaceutical Development; Kalinichev Departs For Neurosterix - Nasdaq